Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Merritt who wrote (398)	2/12/1999 7:03:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 613

Thanks, good stuff! Sounds like everyone is sort of skirting the issue. Experts say.... "don't worry, it doesn't cause tumors, it only enhances the growth of those that already exist." That is, "it's not a carcinogen." Other experts say...... "only a small fraction of transplant recipients have pre-existing tumors." That is, "it'll only lead to a rapid death in a few individuals." Both groups of experts try to reassure you, and sound very expert while doing such. The experts at Novartis say "be happy, don't worry". However, another group of experts will tell you that tumors occur in all individuals, virtually all of the time, and that the immune system controls them. That group of experts would say, correctly, that the increased incidence of herpes virus-induced lymphomas and KS in AIDS patients is evidence for their view. They would also say, therefore, that new transformants might flourish in immunosuppressed individuals, particularly if CyA elicits an "autocrine" growth factor. Experts lavish dogma all over things they don't understand.